More on APRE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.76 |
|
|||
| Open | $0.77 | ||||
| 52 Wk High | $0.08 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $0.78 | ||||
| Day Low | $0.71 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 125,070 | ||||
- Aprea Therapeutics shares Phase 1 data for cancer drug APR-1051
- Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
- Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: Vestal Point Capital, LP
- Form 424B7 Aprea Therapeutics, Inc.
- Aprea (APRE) PT Lowered to $6 at Wedbush
- Aprea Therapeutics (APRE) Misses Q1 EPS by 22c
- Form 10-Q Aprea Therapeutics, Inc. For: Mar 31
- Form 8-K Aprea Therapeutics, Inc. For: May 13
- Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
- Oppenheimer Starts Aprea (APRE) at Outperform
Entities mentioned with APRE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maxim Group | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
